• Hartford HealthCare Medical Group
• Hartford Hospital
• Integrated Care Partners

Omar Eton, MD, an expert with IL2 and cytokine-release syndrome management, arrived at Hartford HealthCare in 2017 as the Cancer Institute’s first medical director of melanoma and skin cancer, overseeing phase 1 trials and the immunotherapy program. He came with a rich work history in the field, starting with an immunology/oncology/hematology fellowship at Memorial Sloan Kettering (MSK) Cancer Center working with the team now leading MSK melanoma efforts. He is most known for “separating apples from oranges” in stage 4 disease prognostic subgroups, developing biochemotherapy, and running the first National Cancer Institute trial in melanoma – with the first response - for Gleevec, ultimately leading to its Food & Drug Administration approval for kit-mutated disease. During this time, he was a reservist with the US Air Force Medical Corps and was recalled for a year after 9/11. He then directed the phase 1 development of an aurora A kinase inhibitor for Millennium Pharmaceuticals in Cambridge, MA, and joined a colleague at Boston University Medical Center, seeing patients with a broad array of oncology and hematology problems for seven years. He enjoys kayaking on the Charles River, hiking the Presidential range in NH, biking, and playing backgammon.

Aetna, Anthem, BCBS Medicare, CarePartners of Connecticut, Cigna Healthcare, Colonial Cooperative Care, Community Health Network of Connecticut, Inc., Connecticare, Connecticare Commercial, Connecticare Medicare, Corvel, Coventry, Essence Healthcare, Evercare, First Health Group Corp., Focus, Harvard Pilgrim, Health Connecticut, Health Direct, Health New England, Healthy Connecticut, HMC/ Northeast Healthcare, Multiplan, Northeast Health Direct, One Health Plan/ Great-West Healthcare, Oxford Health Plans, Prime Health Services, Private Health Care Systems, Inc., Senior Whole Health, United Healthcare, WellCare of Connecticut, Inc.